QLGN - Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06 revenue of $1.4M beats by $0.05M
- Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q2 GAAP EPS of -$0.11 beats by $0.06 .
- Revenue of $1.4M (+25.0% Y/Y) beats by $0.05M .
- As of June 30, 2022, Qualigen Therapeutics had $9.7 million in cash.
- The Company believes its cash is sufficient to fund its anticipated operations into 2023.
For further details see:
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M